C4 Therapeutics Board Of Directors
Marc A. Cohen
Executive Chairman, Board of Directors
Marc A. Cohen is Co-founder and Executive Chairman of C4 Therapeutics. Marc is also the Co-founder and Chief Executive Officer of Bublup, Inc; Neuro Tennis, Inc.; and COBRO Ventures, Inc.; as well as the Co-founder and Chairman of Acetylon Pharmaceuticals, Inc. and OncoPep, Inc., two biotech companies spun out of Dana-Farber Cancer Institute and Harvard University. In addition, Marc was the Co-founder, Chief Executive Officer, and Chairman of OPNET Technologies, Inc (Nasdaq: OPNT), a world leader in network and application performance management. OPNET was sold to Riverbed Technology (Nasdaq: RVBD) in December 2012. Marc received a Bachelor of Science in engineering from Harvard University and a Master of Science in electrical engineering from Stanford University. Marc is a Trustee of the Dana-Farber Cancer Institute where he is focusing on accelerating translational research and increasing the flow of new therapies to patients. Marc enjoys tennis, yoga, and photography, and still hopes to figure out golf one day.
Ken Anderson, MD
Ken is the Kraft Family Professor of Medicine at Harvard Medical School as well as Director of the Jerome Lipper Multiple Myeloma Center and Lebow Institute for Myeloma Therapeutics at Dana-Farber Cancer Institute. His research has pioneered understanding of the tumor microenvironment in multiple myeloma and he has played an extensive role in the development and approval of numerous new treatments for myeloma patients. His research and impact on patient outcomes has been widely recognized including election to the National Institute of Medicine and the Royal Colleges of Physicians and Pathologists and the 2012 American Cancer Society Medal of Honor. He received his MD from Johns Hopkins Medical School, where he also trained in internal medicine, and completed hematology, medical oncology and tumor immunology training at Dana-Farber Cancer Institute. He is a member of the Institute of Medicine of the National Academy of Sciences, served as President of the International Myeloma Society, and is President-elect of the American Society of Hematology.
Bihua Chen is CEO and Portfolio Manager at Cormorant Asset Management. Ms. Chen founded Cormorant Asset Management LLC (“Cormorant”) in 2013 and currently manages investments in public and private biopharmaceutical companies totaling over $800m. Prior to founding Cormorant, Ms. Chen managed a separately managed account focused on the healthcare sector as a sub-adviser to a large, multi-strategy hedge fund based in New York. Ms. Chen obtained an MBA from the Wharton School of Business in 1998 and graduated with a Master of Science, Molecular Biology, from the Graduate School of Biomedical Science at Cornell Medical College in 1994. Ms. Chen also holds a Bachelor of Science degree in Genetics and Genetic Engineering from Fudan University, Shanghai, China, which she received in 1990.
Alain J. Cohen is the Chief Executive Officer, Chief Software Architect, and co-founder of Bublup, Inc., a cloud based application that will transform the way people use the Web. Alain is also CEO and co-founder of COBRO Ventures, Inc., a venture platform, together with his brother, Marc Cohen. Alain co-founded OPNET Technologies (NASD: OPNT), a world leader in application and network performance management. Alain served as OPNET’s President and CTO until its sale in 2012 to Riverbed Technology. Alain is an inventor on more than 60 patents relating to software, networks, electronics, algorithms, and simulation. Alain received a degree in Electrical Engineering from the Massachusetts Institute of Technology. Alain is also an avid tennis player and yogi.
Bruce is a Partner at NewSpring Capital. Bruce was the Chairman and Chief Executive Officer at Barr Pharmaceuticals Inc. from 1994 to 2008. Prior to Barr, he was a Partner at Winston & Strawn LLP and Bishop, Cook, Purcell, and Reynolds. Bruce has been on the Board of Directors for Cardinal Health and Momenta Pharmaceuticals since 2009. He is also on the Board for Acetylon Pharmaceuticals, Inc. and OncoPep. Mr. Downey received a BS degree from Miami University and a JD from Ohio State University. Bruce was the Chairman of Generic Pharmaceutical Association from 2006 to 2007.
Jay is a Co-founder and Principal of EG Capital Group. Previously, Jay was a member of mergers and acquisitions teams at JP Morgan in New York and London. Jay also chairs the Advisory Board at the Naomi Berrie Diabetes Center at Columbia University Medical Center.
Ron Kaiser has over 35 years of Director and executive management experience, serving as a Director, CEO and CFO for public companies and venture-backed portfolio companies in the technology and life sciences industries. Since 1981, he served as CFO during six IPO's or as a CEO for technology companies, and since 2003 as a Director for several public and private companies. He has held executive financial and management roles with Sucampo Pharmaceuticals, OTG Software, Trusted Information Systems, Charmilles Technology Manufacturing Corporation, Leeco Diagnostics, Inc., Somanetics Corporation, and Photon Sources, Inc. Ron is a Principal at Hoffman CFO Consulting, a Certified Board Leadership Fellow of the National Association of Corporate Directors (NACD) and holds dual BA degrees in accounting and multi-disciplinary pre-law from Michigan State University.
Dr. Elena Prokupets co-founded Lenel Systems International and was President, CEO and Chairman of the Board until its sale to United Technology Corporation (UTC). Elena also co-founded and led Edicon Systems, a pioneer in electronic images and electronic photography, that is now owned by Kodak. Elena has MS in Electrical Engineering and PhD in Computer Science. Dr. Prokupets is a Board member of Acetylon Pharmaceuticals Inc, and a Board member of OncoPep Inc, Biotechnology company. Elena is a Trustee of the University of Rochester, and the Managing Director of the Metropolitan Opera of New York.
Malcolm is the James J. Hill Professor, Emeritus, at the Harvard Business School. Since joining the HBS faculty in 1967, his teaching and research focused on issues of corporate strategy and governance. From 1986 to 2006, he also served as president of Mars & Co., a strategy-consulting firm with offices in Greenwich, London, Paris, San Francisco, Tokyo, and Shanghai. Malcolm is a graduate of Harvard University where he received AB, MBA and DBA degrees. Malcolm is a Trustee of the Dana-Farber Cancer Institute.
Bill is Director of Investments for the Kraft Group LLC. Since joining the Kraft Group in 1992, he has been involved with a number of investing and operating initiatives, including the creation of a dedicated family investment office which he now leads today. Bill also serves as Board Member or Observer at Acetylon Pharmaceuticals, Elminda Ltd., Spero Therapeutics and Silk Therapeutics. Bill received a BSBA from Northeastern University and a MSIM from Boston University.
Miles is the Founder and President of Access Capital, a 30 year-old New York based multi-strategy investment firm. The Company is a leading national asset-based lender that is also an active investor in early stage companies and in multi-family real estate. Miles has been on the board of two New York Stock Exchange companies: Diagnostek, a pharmacy benefits company of which he was also Chairman of the Audit Committee; and Newkirk, a real estate investment trust. He was formerly the Vice Chairman of the Board and Chairman of the Investment Committee of Horace Mann School. He is a graduate of Horace Mann, Yale College (BA), NYU Law School (JD) and Harvard Business School (YPO/CEO Program).